LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today...
– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of...
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today...
Imeglimin met its key efficacy endpoint of HbA1c reduction, demonstrating how its unique dual mechanism of action was observed to show added efficacy benefits in combination with existing hypoglycemic agents In particular, Imeglimin was observed to demonstrate...
Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO (NASDAQ: AVRO) (the “Company”), a...
Email
Text